Imprimer

Hydroxyurée, poudre cristalline

Fournisseur: ICN Biomedicals

Synonyms: Hydroxycarbamide

ICNA0210202325EA 496 CHF
ICNA0210202325 ICNA0210202305 ICNA0210202310 ICNA0210202301
Hydroxyurée, poudre cristalline
Hydroxyurée

Hydroxyurea is a inhibitor of DNA synthesis in vivo, and an antiviral and antineoplastic agent which is S-phase specific.


A ribonucleotide reductase inhibitor - inhibits by forming a free radical nitroxide that binds a tyrosyl free radical in the active site of the enzyme. Induces fetal hemoglobin production in sickle cell anemia patients.


It induces apoptosis of in vitro myelogenous leukemia lymphocytes, and the phosphorylation of FADD and p53. It is also used to reduce the rate of painful attacks in sickle-cell disease and has antiretroviral properties in diseases such as AIDS.


It is Anti-neoplastic. It inactivates ribonucleoside reductase by forming a free radical nitroxide that binds a tyrosyl free radical in the active site of the enzyme. This blocks the synthesis of deoxynucleotides, which inhibits DNA synthesis and induces synchronisation or cell death in S-phase.


Freely soluble in water (50 mg/ml-clear colourless solution) or hot alcohol.

Formule: CH₄N₂O₂
MW: 76,05 g/mol
Point d'ébullition: 296 °C (1013 hPa)
Melting Pt: 136…146 °C
MDL Number: MFCD00007943
Numéro CAS: 127-07-1
Merck Index: 13,04874

Order Now

Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Plus About VWR